Eisai's Fycompa launches in Australia for seizures

3 November 2014

Fycompa (perampanel), manufactured by Japanese drug major Eisai (TYO: 4523) has been approved for reimbursement in Australia for the treatment of partial-onset seizures, the most common form of epilepsy, and is now launched in the country.

The drug is indicated for the adjunctive treatment of partial-onset seizures, with or without secondarily-generalized seizures, in patients with epilepsy aged 12 years and older.

Fycompa is the only licensed anti-epileptic drug to selectively target the protein in the brain which plays a critical role in the spread of seizures, and makes it different to other currently-available anti-epileptics. It has a once-daily dosing at bedtime.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK